WO2011034919A3 - Sh2 domain profiling to characterize tyrosine phosphorylation signaling in cancer - Google Patents

Sh2 domain profiling to characterize tyrosine phosphorylation signaling in cancer Download PDF

Info

Publication number
WO2011034919A3
WO2011034919A3 PCT/US2010/048933 US2010048933W WO2011034919A3 WO 2011034919 A3 WO2011034919 A3 WO 2011034919A3 US 2010048933 W US2010048933 W US 2010048933W WO 2011034919 A3 WO2011034919 A3 WO 2011034919A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding
egfr
lung cancer
signaling
domain
Prior art date
Application number
PCT/US2010/048933
Other languages
French (fr)
Other versions
WO2011034919A2 (en
Inventor
Eric B. Haura
Steven A. Eschrich
Bruce J. Mayer
Kazuya Machida
Original Assignee
H. Lee Moffitt Cancer Center And Research Institute, Inc.
University Of Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lee Moffitt Cancer Center And Research Institute, Inc., University Of Connecticut filed Critical H. Lee Moffitt Cancer Center And Research Institute, Inc.
Publication of WO2011034919A2 publication Critical patent/WO2011034919A2/en
Publication of WO2011034919A3 publication Critical patent/WO2011034919A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A phosphoproteomic method termed SH2 profiling to characterize phosphotyrosine (pTyr) signaling in lung cancer. This method provides quantitative values for the phosphorylated binding sites for Src Homology 2 (SH2) domains, which the cell uses to relay signals from tyrosine kinases. Lung cancer cell lines with known mutational status of the epidermal growth factor receptor (EGFR) and Ras were profiled. Changes in SH2 domain binding were characterized in response to the EGFR inhibitor erlotinib, and the SRC/multi-kinase inhibitor dasatinib. Cell lines grouped based on SH2 binding patterns. Clusters correlated with EGFR mutation status or MET activation. Binding of specific SH2 domains correlated with EGFR mutation and erlotinib sensitivity. SH2 domain profiling identifies subsets of lung cancer cells with distinct patterns of pTyr signaling and provides a powerful molecular diagnostic tool for classification and biomarker identification. This analysis has therapeutic importance for personalized use of tyrosine kinase inhibitors in cancer.
PCT/US2010/048933 2009-09-15 2010-09-15 Sh2 domain profiling to characterize tyrosine phosphorylation signaling in cancer WO2011034919A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61/242,423 2009-09-15
US24242309 2009-09-15

Publications (2)

Publication Number Publication Date
WO2011034919A2 WO2011034919A2 (en) 2011-03-24
WO2011034919A3 true WO2011034919A3 (en) 2011-07-21

Family

ID=55637099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/048933 WO2011034919A2 (en) 2009-09-15 2010-09-15 Sh2 domain profiling to characterize tyrosine phosphorylation signaling in cancer

Country Status (1)

Country Link
WO (1) WO2011034919A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021505604A (en) * 2017-12-07 2021-02-18 ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク Regulation and regulation of the function of genetically modified chimeric antigen receptor T cells with dasatinib and other tyrosine kinase inhibitors
WO2019241308A1 (en) * 2018-06-11 2019-12-19 The Regents Of The University Of Colorado, A Body Corporate Effector protein identification by sh2 domain affinity chromatography coupled mass spectrometry
CN114121150B (en) * 2020-08-27 2024-09-20 中国科学院分子细胞科学卓越创新中心 Cancer drug sensitivity prediction method, system, storage medium and terminal

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092079A1 (en) * 1993-09-28 2003-05-15 New York University/Duke University/Sugen Inc. Methods for identifying compounds for treatment of cell proliferative disorders associated with adaptor protein interactions
US20030170737A1 (en) * 2002-03-09 2003-09-11 Cardone Michael H. Cell-based screening methods
US20050119163A1 (en) * 2003-09-18 2005-06-02 The Government Of The United States Of America, As Represented By The Secretary, SH2 domain binding inhibitors
WO2009108637A1 (en) * 2008-02-25 2009-09-03 Prometheus Laboratories, Inc. Drug selection for breast cancer therapy using antibody-based arrays

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092079A1 (en) * 1993-09-28 2003-05-15 New York University/Duke University/Sugen Inc. Methods for identifying compounds for treatment of cell proliferative disorders associated with adaptor protein interactions
US20030170737A1 (en) * 2002-03-09 2003-09-11 Cardone Michael H. Cell-based screening methods
US20050119163A1 (en) * 2003-09-18 2005-06-02 The Government Of The United States Of America, As Represented By The Secretary, SH2 domain binding inhibitors
WO2009108637A1 (en) * 2008-02-25 2009-09-03 Prometheus Laboratories, Inc. Drug selection for breast cancer therapy using antibody-based arrays

Also Published As

Publication number Publication date
WO2011034919A2 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
WO2005118876A3 (en) Egfr mutations
WO2009054939A8 (en) Cancer classification and methods of use
WO2007076523A3 (en) Markers and methods for assessing and treating psoriasis and related disorders
WO2008127718A3 (en) Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2006101925A3 (en) Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2003062395A3 (en) Predictor sets for tyrosine kinase pathways
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
EP2618146A3 (en) Drug selection for breast cancer therapy using antibody-based arrays
WO2007048067A3 (en) C-kit oncogene mutations in melanoma
WO2008030986A3 (en) Molecular diagnosis and classification of malignant melanoma
IN2013CN01129A (en)
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
WO2008153926A3 (en) Inhibitors of receptor tyrosine kinases and methods of use thereof
WO2006002243A3 (en) Methods of oligosaccharide profiling for the detection of cancer
AU2003250657A1 (en) Label-free method for classification and characterization of cellular events
WO2009120561A3 (en) Methods and gene expression signature for assessing growth factor signaling pathway regulation status
WO2006116016A3 (en) Molecular determinants of egfr kinase inhibitor response in glioblastoma
DE602007001103D1 (en) METHOD FOR IDENTIFYING LRRK2-INTERACTIVE MOLECULES AND CLEANING LRRK2
WO2008028031A3 (en) Markers and methods for assessing and treating ulcerative colitis and related disorders using a 43 gene panel
WO2011034919A3 (en) Sh2 domain profiling to characterize tyrosine phosphorylation signaling in cancer
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
WO2006089062A3 (en) Detection of biomarkers for neuropsychiatric disorders
WO2006132970A3 (en) Method for producing improved gene expression analysis and gene expression analysis comparison assay results
MX2010002994A (en) Ligand binding domains of nuclear receptors in controllable form and methods involving the same.
WO2007027421A3 (en) Method for diagnosing non-small cell lung carcinoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10817757

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10817757

Country of ref document: EP

Kind code of ref document: A2